This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of formula I



I

in which

D denotes a mono- or bicyclic aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$ or -C≡CH,

X denotes NR^3 or O,

Y denotes O, S, NH, N-CN or N-NO_2,

R^1 denotes H, Ar, Het, or cycloalkyl,

R^1 may also be A which is optionally mono-, di- or trisubstituted by OR^2, SR^2, $S(O)_mR^2$, $SO_2N(R^2)_2$, SO_3R^2, $S(=O)(=NR^2)R^2$, $NR^2SO_2R^2$, OSO_2R^2, $OSO_2N(R^2)_2$, $N(R^2)_2$, CN, $COOR^2$, $CON(R^2)_2$, Ar, Het or cycloalkyl,

E denotes CH ~~or N~~,

Z is ethylene ~~absent or denotes a $(CH_2)_q$ group, in which one or two CH_2 groups may be replaced by N, O and/or S atoms and/or by a -CH=CH- group and which is unsubstituted or monosubstituted by carbonyl oxygen (=O)~~,

Z' is ethylene ~~absent or denotes a $(CH_2)_q$ group, in which one or two CH_2 groups may be replaced by N, O and/or S atoms and/or by a -CH=CH- group and which is unsubstituted or monosubstituted by carbonyl oxygen (=O)~~,

Q is absent or denotes O, NR^2, C=O, SO_2 or $C(R^2)_n$,

R^2 denotes H, A, $-[C(R^3)_2]_n$-Ar', $-[C(R^3)_2]_n$-Het', $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

R^3 denotes H or A,

R^4, $R^{4'}$ each, independently of one another, is absent or denote A, OH or OA, or R^4 and $R^{4'}$together denote methylene or ethylene,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by =O, =S, =NH, $=NR^3$, $=NOR^3$, $=NCOR^3$, $=NCOOR^3$, $=NOCOR^3$, R^3, Hal, A, $-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het, $-[C(R^3)_2]_n$-cycloalkyl, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, SO_2NR^2 and/or $S(O)_nA$,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$, NR^2COA, NR^2SO_2A, COR^2, $SO_2N(R^2)_2$, $-[C(R^3)_2]_n$-$COOR^2$, $-O-[C(R^3)_2]_o$-$COOR^2$, SO_3H or $S(O)_nA$,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, $SO_2N(R^3)_2$, $S(O)_nA$, $-[C(R^3)_2]_n$-$COOR^3$ or $-O-[C(R^3)_2]_o$-$COOR^3$,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen (=O), =S, $=N(R^2)_2$, Hal, A, $-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het', $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n$-OR^2, $-[C(R^3)_2]_n$-$N(R^3)_2$, NO_2, CN, $-[C(R^3)_2]_n$-$COOR^2$, $-[C(R^3)_2]_n$-$CON(R^2)_2$, $-[C(R^3)_2]_n$-NR^2COA, $NR^2CON(R^2)_2$, $-[C(R^3)_2]_n$-NR^2SO_2A, COR^2, $SO_2N(R^2)_2$ and/or $S(O)_nA$,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, $=N(R^3)_2$, Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, $SO_2N(R^3)_2$ and/or $S(O)_nA$,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2,

o denotes 1, 2 or 3, and

p denotes 1, 2, 3, 4 or 5,

~~q, q' each, independently of one another, denote 0, 1, 2, 3 or 4, where at least one of the groups Z or Z' is present, and~~

~~$0 < q + q' \leq 6$,~~

or a ~~and~~ pharmaceutically usable salt thereof, or a stereoisomer thereof ~~derivatives, solvates, salts and stereoisomers thereof~~, including mixtures thereof in all ratios.

2. (Previously Presented): A compound according to Claim 1, in which D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR^2 or $COOR^2$, or pyridyl which is unsubstituted or monosubstituted by Hal.

3. (Previously Presented): A compound according to Claim 1, in which D denotes phenyl which is monosubstituted by Hal.

4. (Previously Presented): A compound according to Claim 1, in which R^2 denotes H or A.

5. (Previously Presented): A compound according to Claim 1, in which T denotes

a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), or

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OR^2 or NR^2COA, or a monocyclic unsubstituted, saturated carbocycle.

6. (Previously Presented): A compound according to Claim 1, in which Q is absent or denotes O or CH_2.

7. (Previously Presented): A compound according to Claim 1, in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2, NR^2COA, SO_2A, SO_2NH_2, $COOR^2$ or CN.

8. (Previously Presented): A compound according to Claim 1, according to Claim 1 in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3 or NR^3COA.

9. (Previously Presented): A compound according to Claim 1, in which R^1 denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR^2.

10. (Previously Presented): A compound according to Claim 1, in which R^1 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR^3.

11. (Previously Presented): A compound according to Claim 1, in which Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O).

12. (Previously Presented): A compound according to Claim 1, in which Y denotes O.

13. (Previously Presented): A compound according to Claim 1, in which X denotes $NR^{3'}$ or O, and $R^{3'}$ denotes H.

14. (Cancelled):

15. (Previously Presented): A compound according to Claim 1, in which T denotes

a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle.

16. (Previously Presented): A compound according to Claim 1, in which A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F.

17. (Currently Amended): A compound according to Claim 1, in which

D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR^2 or $COOR^2$, or pyridyl which is unsubstituted or monosubstituted by Hal,

X denotes NR^3 or O,

Y denotes O,

R^1 denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR^2,

E denotes CH ~~or N~~,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH_2,

R^2 denotes H or A,

R^3 denotes H or A,

R^4, $R^{4'}$ each, independently of one another, is absent or denote A, OH or OA, or R^4 and $R^{4'}$ together denote methylene or ethylene,

T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2, NR^2COA, SO_2A, SO_2NH_2, $COOR^2$ or CN,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

Hal denotes F, Cl, Br or I, and

p denotes 1, 2, 3, 4 or 5.

18. (Currently Amended): A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes $NR^{3'}$ or O,

Y denotes O,

R^1 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR^3,

$R^{3'}$ denotes H,

E denotes CH ~~or N~~,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH_2,

R^2 denotes H or A,

R^3 denotes H or A,

R^4, $R^{4'}$ each, independently of one another, is absent or denote A, OH or OA, or R^4 and $R^{4'}$ together denote methylene or ethylene,

T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA,

or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and

Hal denotes F, Cl, Br or I.

19. (Currently Amended): A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes $NR^{3'}$ or O,

Y denotes O,

R^1 denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,

or

A, which may be monosubstituted by OR^3,

R^3 denotes H or A,

$R^{3'}$ denotes H,

E denotes CH ~~or N~~,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH_2,

R^2 denotes H or A,

R^3 denotes H or A,

R^4, $R^{4'}$ each, independently of one another, is absent or denote A, OH or OA, or R^4 and $R^{4'}$ together denote methylene or ethylene,

T denotes piperidinyl, piperazinyl, pyridinyl, 2-oxopiperidin-1-yl, 2-oxopiperidin-4-yl, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, morpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxo-piperazin-1-yl, 2,6-dioxopiperazin1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, pyridazinyl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, where the radicals may additionally be monosubstituted by A,

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA,

or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and

Hal denotes F, Cl, Br or I.

20. (Currently Amended): A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes $NR^{3'}$ or O,

Y denotes O,

R^1 denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,

or

A, which may be monosubstituted by OR^3,

R^3 denotes H or A,

$R^{3'}$ denotes H,

E denotes CH ~~or N~~,

Z denotes ethylene,

Z' denotes ethylene,

Q is absent or denotes O or CH_2,

R^2 denotes H or A,

R^3 denotes H or A,

R^4, $R^{4'}$ is absent, or R^4 and $R^{4'}$ together denote methylene or ethylene,

T denotes piperidin-1- or 4-yl, piperazinyl, morpholin-4-yl,

each of which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O),

or unsubstituted cyclohexyl,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and

Hal denotes F, Cl, Br or I.

21. (Currently Amended): A compound according ~~according~~ to Claim 1, wherein said compound is selected from:

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]-urea,

~~(R)-1-(4-chlorophenyl)-3-{2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea,~~

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-fluorophenoxy)piperidin-1-yl]-2-oxo-1-phenylethyl}urea ,

~~(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]urea bistrifluoroacetate,~~

~~(R)-1-(4-chlorophenyl)-3-{2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,~~

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

~~(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-3-ylmethylpiperazin-1-yl)-ethyl]urea bistrifluoroacetate,~~

~~(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(4-pyridin-4-ylpiperazin-1-yl)-methanoyl]propyl}urea bistrifluoroacetate,~~

~~(R,R)-1-(4-chlorophenyl)-3-(2-methoxy-1-{1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methanoyl}propyl)urea bistrifluoroacetate,~~

(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(1'-methyl-4,4'-bipiperidinyl-1-yl)-methanoyl]propyl}urea trifluoroacetate,

~~(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]urea,~~

~~(R)-1-(4-chlorophenyl)-3-[1-(4-pyridin-4-ylpiperazine-1-carbonyl)butyl]urea,~~

(R)-1-(4-chlorophenyl)-3-{2-[4-hydroxy-4-(4-methoxyphenyl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea,

~~(R)-1-(4-chlorophenyl)-3-{2-[4-(2-methoxyphenyl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea,~~

(R)-N-[4-(1-{2-[3-(4-chlorophenyl)ureido]-2-phenylethanoyl}piperidin-4-ylmethyl)-phenyl]acetamide,

(R)-1-(4-chlorophenyl)-3-{2-oxo-1-phenyl-2-[4-(1-phenylmethanoyl)piperidin-1-yl]-ethyl}urea,

~~(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]urea,~~

~~(R)-1-[2-(4-benzylpiperazin-1-yl)-2-oxo-1-phenylethyl]-3-(4-chlorophenyl)urea,~~

~~(R)-1-(4-chlorophenyl)-3-{2-[5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-oxo-1-phenylethyl}urea,~~

~~(R)-1-(4-chlorophenyl)-3-{2-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea,~~

(R,S)-1-[2-(3-benzylpiperidin-1-yl)-2-oxo-1-phenylethyl]-3-(4-chlorophenyl)urea,

~~(S,S)-1-(4-chlorophenyl)-3-{2-hydroxy-1-[1-(4-pyridin-4-ylpiperazin-1-yl)-methanoyl]propyl}urea,~~

~~(S,S)-1-(4-chlorophenyl)-3-(2-hydroxy-1-{1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methanoyl}propyl)urea,~~

~~(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(4-pyridin-3-ylmethylpiperazin-1-yl)-methanoyl]propyl}urea bistrifluoroacetate,~~

~~(R)-1-(4-chlorophenyl)-3-[2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]urea bistrifluoroacetate,~~

(R,R)-1-(4-chlorophenyl)-3-(1-{1-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-methanoyl}-2-methoxypropyl)urea bistrifluoroacetate,

~~(R)-1-(4-chlorophenyl)-3-{2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,~~

(R)-1-(2-4,4'-bipiperidinyl-1-yl-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-[2-4,4'-bipiperidinyl-1-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)-urea hydrochloride,

(R)-1-(2-4,4'-bipiperidinyl-1-yl-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl]urea trifluoroacetate,

1-[2-[1,4']bipiperidinyl-1'-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)-urea,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl]-urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

~~(R)-1-(4-chlorophenyl)-3-[2-(4-cyclohexylpiperazin-1-yl)-1-(4-hydroxyphenyl)-2-oxoethyl]urea trifluoroacetate,~~

~~(R)-1-(4-chlorophenyl)-3-[2-(4-cyclohexylpiperazin-1-yl)-2-oxo-1-phenylethyl]urea trifluoroacetate,~~

(R)-1-(4-chlorophenyl)-3-{1-(4-hydroxyphenyl)-2-[4-(4-methylpiperazin-1-yl)-piperidin-1-yl]-2-oxoethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

~~(R)-1-(4-chlorophenyl)-3-[2-(4-cyclohexylpiperazin-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,~~

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-thiophen-2-ylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea,

(R)-1-(4-chlorophenyl)-3-[2-(4,4'-bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]-urea,

(R)-1-(4-chlorophenyl)-3-[1-(2-chlorophenyl)-2-(1'-methyl-2'-oxo-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea,

(R)-1-(4-chlorophenyl)-3-[1-phenyl-2-(1'-methyl-2'-oxo-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea,

2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl (R)-4-chlorophenyl)-

carbamate,

~~2-oxo-1-phenyl-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl (R)-(4-chlorophenyl)carbamate,~~

2-4,4'-bipiperidinyl-1-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-carbamate hydrochloride,

2-4,4'-bipiperidinyl-1-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate hydrochloride,

1-(2-chlorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

1-(2-chlorophenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-carbamate trifluoroacetate,

2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)-carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

~~1-(2-chlorophenyl)-2-(4-cyclohexylpiperazin-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)-carbamate trifluoroacetate,~~

~~2-(4-cyclohexylpiperazin-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,~~

1-(2-chlorophenyl)-2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxoethyl (R)-(4-chlorophenyl)carbamate bistrifluoroacetate,

2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate bistrifluoroacetate,

1-(2,3-difluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate,

1-(2-fluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate,

1-(2-methoxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate,

and pharmaceutically usable ~~derivatives, solvates,~~ salts and stereoisomers thereof, including mixtures thereof in all ratios.

22. (Previously Presented): A process for the preparation of a compound according to Claim 1, said process comprising

a) for the preparation of compounds

X denotes NH and

Y denotes O,

reacting a compound of formula II



II

with a compound of formula III

III,

or

b) for the preparation of compounds

in which

X and Y denote O,

reacting a compound of formula IV



IV,

with a compound of formula V



V

in which

X and Y denote O, and

L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or a base or acid of formula I is converted into one of its salts.

23. (Previously Presented): A method of inhibiting coagulation factor Xa in a patient, comprising administering to said patient an effective amount of a compound of claim 1.

24. (Previously Presented): A method of inhibiting coagulation factor VIIa in a patient, comprising administering to said patient an effective amount of a compound of claim 1.

25. (Previously Presented): A pharmaceutical composition comprising a compound according to Claim 1, and one or more excipients and/or adjuvants.

26. (Previously Presented): A pharmaceutical composition comprising a compound according to Claim 1, and at least one further medicament active ingredient.

27. (Previously Presented): A method of treating a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, said method comprising administering to said patient an effective

amount of a compound according to claim 1.

28. (Previously Presented): A kit comprising a first and second separate packs, said first pack containing an effective amount of a compound according to Claim 1, and said second pack containing an effective amount of a further medicament active ingredient.

29. (Previously Presented): A method according to claim 27, further comprising administering to said patient at least one further medicament active ingredient.

30. (Currently Amended): A compound according to claim 1, wherein ~~E is or N, Z and Z' are each ethylene, and~~ Q is absent.

31. (Previously Presented): A compound according to claim 30, wherein X is NR^3 and Y is O.

32. (Previously Presented): A compound according to claim 30, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

33. (Previously Presented): A compound according to claim 31, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

34. (Previously Presented): A compound according to claim 30, wherein R^1 is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

35. (Previously Presented): A compound according to claim 33, wherein R^1 is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

36. (Previously Presented): A compound according to claim 30, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy,

ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

37. (Previously Presented): A compound according to claim 35, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

38. (New): A method of treating a patient suffering from thrombosis comprising administering to said patient an effective amount of a compound according to claim 1.

39. (New): A method of treating a patient suffering from thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, venous thrombosis, pulmonary embolism, arterial thrombosis, myocardial ischaemia, unstable angina or a stroke based on thrombosis, said method comprising administering to said patient an effective amount of a compound according to claim 1.